Xian C J, Upton Z, Goddard C, Shoubridge C A, McNeil K A, Wallace J C, Read L C, Francis G L
Child Health Research Institute, North Adelaide, South Australia.
J Mol Endocrinol. 1996 Feb;16(1):89-97. doi: 10.1677/jme.0.0160089.
This study describes the biosynthesis of a human epidermal growth factor fusion protein, Long EGF, that has a 53 amino acid extension peptide derived from the 46 N-terminal amino acids of porcine GH. The approach allowed the production of Long EGF at high efficiency due to the expression of the fusion protein in high yield as inclusion bodies in Escherichia coli. Long EGF had a slightly lower potency compared with native EGF in a range of assays, including binding to anti-EGF antibodies or the EGF receptor, stimulation of Balb/3T3 fibroblast and rat intestinal epithelial cell growth, as well as counteracting the inhibition of mink lung epithelial cell proliferation by transforming growth factor-beta 1. Degradation of Long EGF and native EGF was compared in gastrointestinal flushings as an indication of whether the EGF domain of the fusion protein would be protected from proteolytic cleavage and be useful as a trophic agent in the gut. Incubation with flushings from the stomach or jejunum of rats caused rapid cleavage of the extension peptide, releasing native EGF. A C-terminal truncation of Arg53 in the stomach and a removal of the C-terminal pentapeptide (49 Trp-Trp-Glu-Leu-Arg53) in the small bowel was demonstrated by N-terminal sequencing and mass spectrometry. The degradation patterns were reflected by changes in migration of products on SDS-PAGE and in subsequent binding activities to the EGF receptor and anti-EGF antibodies. The data show that a human EGF fusion protein can be produced efficiently in a bacterial expression system and that it retains biological activity in vitro. Although the extension peptide was rapidly cleaved from Long EGF in both stomach and small bowel producing similar biological activity to native EGF, it could not prevent subsequent degradation of the EGF domain. Other strategies are being investigated to develop an effective oral form of EGF that resists digestion by proteases in the gastrointestinal tract.
本研究描述了一种人表皮生长因子融合蛋白Long EGF的生物合成,该蛋白具有一个由猪生长激素46个N端氨基酸衍生而来的53个氨基酸的延伸肽。由于融合蛋白以包涵体形式在大肠杆菌中高效表达,这种方法能够高效生产Long EGF。在一系列检测中,包括与抗EGF抗体或EGF受体结合、刺激Balb/3T3成纤维细胞和大鼠肠上皮细胞生长,以及抵消转化生长因子-β1对貂肺上皮细胞增殖的抑制作用,Long EGF的效力略低于天然EGF。在胃肠道冲洗液中比较了Long EGF和天然EGF的降解情况,以此表明融合蛋白的EGF结构域是否能免受蛋白水解切割,并作为肠道中的营养因子发挥作用。用大鼠胃或空肠的冲洗液孵育会导致延伸肽迅速裂解,释放出天然EGF。通过N端测序和质谱分析证实,在胃中Arg53的C端截短,在小肠中C端五肽(49 Trp-Trp-Glu-Leu-Arg53)被去除。降解模式通过SDS-PAGE上产物迁移的变化以及随后与EGF受体和抗EGF抗体的结合活性反映出来。数据表明,人EGF融合蛋白可以在细菌表达系统中高效生产,并且在体外保留生物活性。尽管延伸肽在胃和小肠中都能从Long EGF上迅速裂解,产生与天然EGF相似的生物活性,但它并不能阻止EGF结构域随后的降解。正在研究其他策略来开发一种有效的口服形式的EGF,使其能抵抗胃肠道中蛋白酶的消化。